Targeted sequencing of tubo-ovarian and peritoneal high-grade serous carcinoma with wild-type p53 immunostaining pattern

Han Na Kim, Ha Young Woo, Sung Im Do, Hyun Soo Kim

Research output: Contribution to journalArticle

Abstract

Background/Aim: We aimed to demonstrate the use of next-generation sequencing (NGS) to confirm the presence of tumor protein 53 (TP53) mutations in tuboovarian and peritoneal high-grade serous carcinoma (HGSC) with a wild-type p53 immunostaining pattern and investigate whether the TP53 mutational status is altered by chemotherapy. Materials and Methods: A commercial NGS panel comprising 171 genes was used to analyze the genetic profiles of 15 HGSC samples. Paired specimens obtained before and after chemotherapy were available for four patients. Results: All examined samples exhibited TP53 mutations. For all the patients who underwent neoadjuvant or postoperative adjuvant chemotherapy, TP53 mutations identified in samples obtained after chemotherapy were the same as those detected in pre-chemotherapeutic samples. Conclusion: HGSCs exhibit TP53 mutations even though a subset of HGSCs displayed a wild-type p53 immunostaining pattern. Chemotherapy does not affect the TP53 mutational status in HGSC.

Original languageEnglish
Pages (from-to)1485-1492
Number of pages8
JournalIn Vivo
Volume33
Issue number5
DOIs
Publication statusPublished - 2019 Jan 1

Fingerprint

Chemotherapy
Tumors
Carcinoma
Drug Therapy
Neoplasms
Mutation
Proteins
Adjuvant Chemotherapy
Genes

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology

Cite this

@article{4d9b4112199849c0a2ddaba491434e43,
title = "Targeted sequencing of tubo-ovarian and peritoneal high-grade serous carcinoma with wild-type p53 immunostaining pattern",
abstract = "Background/Aim: We aimed to demonstrate the use of next-generation sequencing (NGS) to confirm the presence of tumor protein 53 (TP53) mutations in tuboovarian and peritoneal high-grade serous carcinoma (HGSC) with a wild-type p53 immunostaining pattern and investigate whether the TP53 mutational status is altered by chemotherapy. Materials and Methods: A commercial NGS panel comprising 171 genes was used to analyze the genetic profiles of 15 HGSC samples. Paired specimens obtained before and after chemotherapy were available for four patients. Results: All examined samples exhibited TP53 mutations. For all the patients who underwent neoadjuvant or postoperative adjuvant chemotherapy, TP53 mutations identified in samples obtained after chemotherapy were the same as those detected in pre-chemotherapeutic samples. Conclusion: HGSCs exhibit TP53 mutations even though a subset of HGSCs displayed a wild-type p53 immunostaining pattern. Chemotherapy does not affect the TP53 mutational status in HGSC.",
author = "Kim, {Han Na} and Woo, {Ha Young} and Do, {Sung Im} and Kim, {Hyun Soo}",
year = "2019",
month = "1",
day = "1",
doi = "10.21873/invivo.11628",
language = "English",
volume = "33",
pages = "1485--1492",
journal = "In Vivo",
issn = "0258-851X",
publisher = "International Institute of Anticancer Research",
number = "5",

}

Targeted sequencing of tubo-ovarian and peritoneal high-grade serous carcinoma with wild-type p53 immunostaining pattern. / Kim, Han Na; Woo, Ha Young; Do, Sung Im; Kim, Hyun Soo.

In: In Vivo, Vol. 33, No. 5, 01.01.2019, p. 1485-1492.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Targeted sequencing of tubo-ovarian and peritoneal high-grade serous carcinoma with wild-type p53 immunostaining pattern

AU - Kim, Han Na

AU - Woo, Ha Young

AU - Do, Sung Im

AU - Kim, Hyun Soo

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Background/Aim: We aimed to demonstrate the use of next-generation sequencing (NGS) to confirm the presence of tumor protein 53 (TP53) mutations in tuboovarian and peritoneal high-grade serous carcinoma (HGSC) with a wild-type p53 immunostaining pattern and investigate whether the TP53 mutational status is altered by chemotherapy. Materials and Methods: A commercial NGS panel comprising 171 genes was used to analyze the genetic profiles of 15 HGSC samples. Paired specimens obtained before and after chemotherapy were available for four patients. Results: All examined samples exhibited TP53 mutations. For all the patients who underwent neoadjuvant or postoperative adjuvant chemotherapy, TP53 mutations identified in samples obtained after chemotherapy were the same as those detected in pre-chemotherapeutic samples. Conclusion: HGSCs exhibit TP53 mutations even though a subset of HGSCs displayed a wild-type p53 immunostaining pattern. Chemotherapy does not affect the TP53 mutational status in HGSC.

AB - Background/Aim: We aimed to demonstrate the use of next-generation sequencing (NGS) to confirm the presence of tumor protein 53 (TP53) mutations in tuboovarian and peritoneal high-grade serous carcinoma (HGSC) with a wild-type p53 immunostaining pattern and investigate whether the TP53 mutational status is altered by chemotherapy. Materials and Methods: A commercial NGS panel comprising 171 genes was used to analyze the genetic profiles of 15 HGSC samples. Paired specimens obtained before and after chemotherapy were available for four patients. Results: All examined samples exhibited TP53 mutations. For all the patients who underwent neoadjuvant or postoperative adjuvant chemotherapy, TP53 mutations identified in samples obtained after chemotherapy were the same as those detected in pre-chemotherapeutic samples. Conclusion: HGSCs exhibit TP53 mutations even though a subset of HGSCs displayed a wild-type p53 immunostaining pattern. Chemotherapy does not affect the TP53 mutational status in HGSC.

UR - http://www.scopus.com/inward/record.url?scp=85071740477&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071740477&partnerID=8YFLogxK

U2 - 10.21873/invivo.11628

DO - 10.21873/invivo.11628

M3 - Article

C2 - 31471396

AN - SCOPUS:85071740477

VL - 33

SP - 1485

EP - 1492

JO - In Vivo

JF - In Vivo

SN - 0258-851X

IS - 5

ER -